Show simple item record

dc.contributor.authorNaing, A
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorSpira, AI
dc.contributor.authorGarcia-Corbacho, J
dc.contributor.authorRandhawa, M
dc.contributor.authorEskens, F
dc.contributor.authorO'Neil, B
dc.contributor.authorLavernia, J
dc.contributor.authorUboha, NV
dc.contributor.authorHamid, O
dc.contributor.authorEl-Khoueiry, A
dc.contributor.authorBenson, BA
dc.contributor.authorGarner, W
dc.contributor.authorHuels, VJ
dc.contributor.authorArkenau, HT
dc.contributor.authorLorusso, P
dc.date.accessioned2019-11-19T16:01:07Z
dc.date.available2019-11-19T16:01:07Z
dc.date.issued2019en
dc.identifier.citationNaing A, Thistlethwaite FC, Spira AI, Garcia-Corbacho J, Randhawa M, Eskens F, et al. CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072. J Clin Oncol. 2019;37(15_suppl):2513-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.2513en
dc.identifier.urihttp://hdl.handle.net/10541/622459
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2513en
dc.titleCX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMD Anderson Cancer Center, Houston, TXen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record